Stage IV lung squamous cell cancer with bone metastasis and immunotherapy-related adrenal insufficiency

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: rib/bone

After earlier progression with rib/bone destruction, the latest chest CT showed lung lesions similar to prior imaging. Tislelizumab remained paused because of adrenal insufficiency.

PubMed CentralRead more →

Stage IV lung squamous cell cancer complicated by adrenal insufficiency during immunotherapy

Patient Info: Anonymized, male, 50s | Stage IV

Mediastinal and hilar lymph nodes improved on treatment. Immunotherapy remained paused because of adrenal insufficiency, and updated follow-up found no recurrence or additional metastasis.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Lenny's Survivor Story

Patient Info: Lenny, Male, 50s | Stage IV

Biomarkers: PD-L1 expression positive

Metastatic Site: right femur; brain/cerebellum

As of July 2024, Lenny described himself as NED/no evidence of disease after surgery, CyberKnife radiation, chemotherapy, and Keytruda-based immunotherapy.

The Patient StoryRead more →

Five-year survival with extensive-stage small cell lung cancer on atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: bilateral lungs, cervical lymph nodes

Five years after diagnosis with extensive-stage small cell lung cancer, he was alive and well on maintenance atezolizumab with no further documented progression after the 2020–2021 rechallenge, reaching 60 months overall survival and about 44 months progression-free survival.

PubMed CentralRead more →

Treatment-related lung injury during therapy for Stage IV squamous lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

A 63-year-old man with Stage IV squamous lung cancer developed interstitial lung disease soon after starting chemotherapy and immunotherapy, with respiratory findings improving after steroid treatment.

PubMed CentralRead more →

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed CentralRead more →

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed CentralRead more →

Stage 4 lung adenocarcinoma: complete response on immunotherapy combination

Patient Info: Anonymized, Male | Stage IV

Biomarkers: No targetable mutation found. Tissue showed TP53/ARID1A; liquid biopsy added KEAP1, and SMARCA4. PD-L1 not evaluable.

Metastatic Site: bilateral lung nodules, left adrenal gland

As of May 2024, metastatic lung adenocarcinoma had a complete radiologic response lasting more than 14 months on pembrolizumab maintenance, and a new PET-avid lung nodule was benign inflammation rather than cancer.

PubMed CentralRead more →

Small cell lung cancer with SIADH that progressed after an initial response to treatment

Patient Info: Anonymized, female, 60s | Stage IV

Metastatic Site: liver

The cancer progressed with disseminated liver metastases, and she died from liver failure in February 2021.

PubMed CentralRead more →

Stage IV lung adenocarcinoma with brain metastases and an aortic blood clot

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: KRAS ; EIF1AZ mutation; PD-L1 30%

Metastatic Site: brain

She remained in active care after whole-brain radiation, with systemic chemo-immunotherapy planned for Stage IV lung adenocarcinoma.

PubMed CentralRead more →

SMARCA4-deficient undifferentiated lung cancer with pleural disease and later spinal metastasis

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: BRCA1 p.S1796 variant; TP53 p.; tumor mutational burden 12.6

Metastatic Site: spine

After chemotherapy and one cycle of nivolumab, a new 4.5 cm spinal metastasis caused cord compression and required surgery; further outpatient treatment was planned.

PubMed CentralRead more →

Stage IV BRAF-mutated lung adenocarcinoma responding to second-line chemo-immunotherapy

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: BRAF exon 15 p.T599dup; PD-L1 5%

Metastatic Site: pleura, pericardium

After progression on BRAF/MEK-targeted therapy, second-line chemo-immunotherapy produced a partial response that was still ongoing after about 1 year of second-line treatment.

PubMed CentralRead more →

Stage IV lung adenocarcinoma complicated by immunotherapy-related perimyocarditis

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 <1%

She died from cancer progression 3 months after recovering from immunotherapy-related perimyocarditis.

PubMed CentralRead more →

Stage IV enteric-type lung adenocarcinoma with EGFR mutations and MSI-high disease

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; MSI-high; high tumor mutation burden; MLH1 mutation; pMMR; PD-L1-negative

Metastatic Site: lung, pleura

The cancer progressed through multiple targeted, chemotherapy, and immunotherapy regimens. He died about 30 months after the initial diagnosis.

PubMed CentralRead more →

Rare lung cancer first discovered as a mass in the skull

Patient Info: Anonymized, Male | Stage IV

Biomarkers: KRAS ; CK7-positive; CDX2-positive; pathology favoured pulmonary enteric adenocarcinoma

Metastatic Site: skull base / sphenoid sinus; right posterior acetabulum

He received palliative radiation and prolonged systemic therapy, completing 35 cycles including 31 maintenance cycles of pemetrexed and pembrolizumab.

PubMed CentralRead more →

Stage IV lung adenocarcinoma followed without treatment after chemotherapy and pembrolizumab caused kidney injury

Patient Info: Anonymized, female | Stage IV

Metastatic Site: liver, pleura

After stopping antitumor drugs, follow-up imaging and tumor markers showed no evidence suggesting cancer recurrence.

PubMed CentralRead more →

Brain radiation therapy complication (radionecrosis) potentially linked to combined chemo-immunotherapy

Patient Info: Anonymized, Female | Stage IV

Biomarkers: PD-L1 0%; tumour mutational burden 33 mutations/Mb; TP53 mutation at diagnosis; later ctDNA included KEAP1 and NOTCH3 alterations

Metastatic Site: brain; presumed leptomeningeal disease

She recovered completely from surgery for radiation necrosis, resumed cancer treatment and remained neurologically intact at 18 months. She was found deceased 9 months later; the cause of death was unknown.

PubMed CentralRead more →

BRCA2-Mutated Metastatic Lung Adenocarcinoma Controlled for 30 Months With Olaparib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: PD-L1-negative; BRCA2 mutation; ATM mutation; EGFR-negative; ALK-negative

Metastatic Site: brain

Olaparib provided about 30 months of disease control, and PET imaging remained overall stable when a separate new breast primary was found in February 2023.

PubMed CentralRead more →

HER2-positive metastatic lung cancer treated with trastuzumab deruxtecan (Enhertu)

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ERBB2/HER2 copy-number gain of at least 20 copies; TP53 C242fs; CDK12 copy-number gain; tumour mutational burden 3.2 mutations/Mb

Metastatic Site: lungs / multiple pulmonary nodules

Trastuzumab deruxtecan reduced the pulmonary nodules by more than 50% at 3 months and produced a documented response lasting 13.8 months.

PubMed CentralRead more →

Afatinib-related kidney injury during treatment for EGFR-positive metastatic lung cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR-positive.

Metastatic Site: pleura

He continued maintenance bevacizumab and atezolizumab after four combination courses for metastatic disease while his renal function remained impaired but stable.

PubMed CentralRead more →

Stage IV Lung Cancer Reached Remission After Severe Nerve Damage and Neck Surgery

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: left cervical lymph nodes

Considered in complete remission after cervical lymph-node surgery, with no clinical or radiological progression 24 months after systemic treatment; alive and back at work 3 years after diagnosis.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Shyreece's Patient Story

Patient Info: Shyreece, Female | Stage IV

Biomarkers: ALK rearrangement / ALK-positive

Metastatic Site: Brain

As of March 2022, Shyreece was a long-term Stage IV ALK-positive lung cancer survivor with later brain metastases, ongoing treatment decisions, and advocacy focused on biomarker testing, trials, and disparities in Black lung cancer care.

The Patient StoryRead more →

Pembrolizumab Controlled Metastatic Pleomorphic Lung Cancer After Chemotherapy Failed

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; BRAF-negative; PD-L1 TPS 60%-70%; BRCA2, and TP53 mutations; tumor mutation burden 42 mutations/Mb; no actionable alteration.

Metastatic Site: right adrenal gland; left adrenal gland; bone

Tumor diameter had decreased at 11 months, and pembrolizumab remained ongoing at 12 months.

PubMed CentralRead more →

A painful scalp metastasis from sarcomatoid lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: No targetable mutations identified; CAM5.2-positive; p63-positive; CD10-positive; vimentin-positive.

Metastatic Site: chest wall and rib; liver; right gluteal region; scalp…

Her disease progressed with a further liver lesion and additional metastatic complications, and systemic treatment was stopped because of severe immune-related toxicity and the absence of targetable mutations.

PubMed CentralRead more →